Wanbury reports robust Q2 & H1 FY26 results with 216.6% YoY PAT jump to ₹28.7 crore
Wanbury reports strong Q2 & H1 FY26 financial results with a 216.6% YoY PAT jump to ₹28.7 crore, driven by volume growth, cost efficiencies, and improved product yield.
Strong financial performance, especially robust growth in PAT and EBITDA with improved margins, is a key positive indicator for a company's health and future prospects, likely leading to a significant positive market reaction.
The company reported substantial year-on-year growth in PAT (89.3% for Q2, 216.6% for H1) and EBITDA (20.1% for Q2, 51.3% for H1), alongside significant improvements in margins. The management commentary reinforces a positive outlook, attributing success to strategic initiatives and operational efficiencies.
Wanbury Limited has announced its financial results for the quarter and half year ended 30th September 2025. * Q2 FY26 Financial Highlights (YoY comparison with Q2 FY25): * Revenue from operations stood at ₹160.1 crore, a slight decrease of 0.7% YoY from ₹161.2 crore. * EBITDA (including other income) increased by 20.1% YoY to ₹26.0 crore, up from ₹21.6 crore. EBITDA Margin improved by 292 bps to 16.2%. * PAT for the quarter surged by 89.3% YoY to ₹15.2 crore, compared to ₹8.0 crore. PAT Margin improved by 455 bps to 9.5%. * These improvements were primarily driven by cost efficiencies, improved product yield, and lower finance costs. * H1 FY26 Financial Highlights (YoY comparison with H1 FY25): * Revenue from operations for H1 FY26 grew by 10.6% YoY to ₹323.2 crore, up from ₹292.3 crore, led by volume growth. * EBITDA (including other income) for H1 FY26 increased by 51.3% YoY to ₹50.8 crore, up from ₹33.6 crore. EBITDA Margin improved by 430 bps to 15.7%. * PAT for H1 FY26 saw a significant jump of 216.6% YoY to ₹28.7 crore, compared to ₹9.1 crore. PAT Margin improved by 578 bps to 8.9%. * Overall H1 growth was attributed to volume growth, cost efficiencies, improved product yield, and lower finance costs. * Management Commentary: * Mr. Mohan Rayana, Director of Wanbury Ltd., commented that Q2 continues to be stronger with a robust EBITDA of ₹26.0 crore and PAT of ₹15.2 crore. This improvement was driven by several technical initiatives, enhanced product yields, and higher procurement efficiencies. He also highlighted the Formulations business turning EBITDA positive, supported by the successful launch of a new brand (C-red-advanced liposomal iron supplement) and improved field productivity. The company's CAPEX plan is on track for introducing new products, increasing capacities, and maintaining operational efficiencies.
What to do with a filing like this
Wanbury Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wanbury Limited. Read the original for the full detail.